At Rally Round Rupert, 2024 was a year of progress, passion, and profound impact. As we reflect on the past twelve months, we’re proud to share the milestones captured in our RRR Annual Report 2025 —a testament to what can be achieved when a community comes together with a shared mission: to support families affected by Spinal Muscular Atrophy (SMA) and accelerate clinical research that changes lives.

💙 Our Mission in Action

Our charitable purpose remains firmly rooted in two key pillars:

With your support, we were able to turn these aims into real, measurable action throughout the year.

🚶‍♂️ The 100 WALK 100: A Landmark Event

One of the highlights of our year was the incredible 100 WALK 100 event. In June 2024, more than 100 participants walked 100 miles along the beautiful Cotswold Way over three days. Not only did the event generate an astounding £110,000 in donations, but it also gained widespread media attention, helping us shine a light on SMA like never before.

The journey began in Chipping Campden and ended at the historic Bath Cathedral—a powerful reminder that every step counts in the journey toward medical progress.

🧪 Advancing Research with Leading Institutions

Thanks to the generosity of our supporters, we were able to fund two major research projects in 2024:

These initiatives are more than numbers—they represent hope, innovation, and the power of partnership.

🔭 Looking Ahead

Building on a successful year, we’re excited to share that we’re in discussions with NHS Sheffield Children’s Hospital about a new clinical research project ‘SMA Spinal Management Study’. We’ll keep you updated as the plans develop throughout 2025.

💬 A Thank You from the Trustees

We want to extend a heartfelt thank you to everyone who supported us in 2024. Whether you donated, walked, volunteered, or simply shared our story—you are part of the change. As a charity led by a passionate group of trustees and powered by community spirit, we couldn’t do this without you.

📊 Financial Highlights

Here’s a snapshot of our financial activity:

We remain financially stable, with adequate reserves to fund future research while maintaining our operational commitments.

Together, we’re making strides in the fight against SMA.